SLRN Acelyrin
- 3.300
- +0.160+5.10%
- 3.300
- 0.0000.00%
Acelyrin News
Acelyrin | 8-K: Current report
Acelyrin | 4: Statement of changes in beneficial ownership of securities-Officer Murugan Amar
Acelyrin | EFFECT: Others
Acelyrin | 3: Initial statement of beneficial ownership of securities-Officer Murugan Amar
Acelyrin | CORRESP: CORRESP
Acelyrin | UPLOAD: Others
Acelyrin | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-T. Rowe Price Investment Management, Inc.(10.5%)
Acelyrin | S-3: Registration statement for specified transactions by certain issuers
Acelyrin | 8-K: Current report
Acelyrin | 10-Q: Q3 2024 Earnings Report
Acelyrin | 8-K: ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
Acelyrin | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(4.07%)
Acelyrin | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(6.0%)
Acelyrin | 8-K/A: Current report (Amendment)
Acelyrin | SC 13G: Statement of acquisition of beneficial ownership by individuals-The Vanguard Group(4.07%)
Acelyrin | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(6.0%)
Acelyrin | SC 13G: Statement of acquisition of beneficial ownership by individuals-T. Rowe Price Investment Management, Inc.(10.5%)
Acelyrin | 4: Statement of changes in beneficial ownership of securities-Officer Labrucherie Gil M
Acelyrin | 10-Q: Q2 2024 Earnings Report
Acelyrin | 8-K: ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
No Data